Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EONS Poster diplay

1615 - EONS Poster - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: a systematic review


22 Oct 2018


EONS Poster diplay



Tumour Site


Sara Colomer-Lahiguera


Annals of Oncology (2018) 29 (suppl_8): viii689-viii693. 10.1093/annonc/mdy341


S. Colomer-Lahiguera1, D. Bryant-Lukosius2, S. Rietkoetter2, L. Martelli2, K. Ribi3, A. Orcurto4, R. Juergens5, M. Eicher1

Author affiliations

  • 1 Department Of Oncology - Institute Of Higher Education And Research In Healthcare (iufrs), Centre Hospitalier Universitaire Vaudois (CHUV), 1010 - Lausanne/CH
  • 2 School Of Nursing/department Of Oncology, McMaster University, Hamilton/CA
  • 3 Institute Of Higher Education And Research In Healthcare (iufrs), University of Lausanne, 1010 - Lausanne/CH
  • 4 Department Of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), 1011 - Lausanne/CH
  • 5 Division Of Medical Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton/CA

Abstract 1615


ICI have shown significant clinical benefit for patients diagnosed with varied types of cancer. With an increasing use of these therapies, it is of urgent interest to achieve a comprehensive understanding of the overall patient experience – thus PROs should be systematically included in clinical ICI trials. We conducted a systematic review of published literature to identify and categorize PRO instruments and examine related utility and measurement issues in studies reporting on ICI.


Literature was searched using PubMed, Embase, PsycINFO, Medline and CINAHL databases (June 2017). Search terms included controlled vocabulary and specific keywords related to: (1) Food and Drug Administration (FDA) approved ICI, (2) PRO, and (3) Oncology. Eight reviewers independently screened titles/abstracts followed by a full text selection based on predefined criteria. We included clinical trials, intervention studies, systematic reviews, study protocols, observational studies, and case reports. Information regarding the clinical trial protocol and PRO tools was collected. (PROSPERO CRD42018090912).


Of the 24 articles included in the review, 13 reported PRO data from primary clinical studies, nine were quality-adjusted life year analyses, and two were study protocols. These articles referred to a total of 14 clinical trials reporting PRO results. Of these, 12 used cancer-specific (11 EORTC-QLQ-C30 and 1 FACT-G) and 11 a generic quality of life (QoL) questionnaire (10 EQ-5D and 1 SF-36). Whereas in seven cases, only cancer-specific and generic questionnaires were used, five studies combined them with disease-specific modules, and two included a symptom-specific questionnaire. Furthermore, six studies used PROs to conduct analyses of health economics and work productivity.


Cancer-specific or generic QoL questionnaires are the most widely used PRO measures in clinical ICI trials. As ICI therapies exhibit unique characteristics different from conventional cancer therapies, such broad instruments may not capture the specific ICI-related symptoms, toxicities, and impact on the patient’s QoL. Hence, the adaptation or development of ICI specific PRO tools should be further investigated.

Clinical trial identification

Legal entity responsible for the study

Centre Hospitalier Universitaire Vaudois (CHUV) - University of Lausanne (UNIL) and McMaster University.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.